Would you recommend PARP inhibitor maintenance for a BRCA wild-type, HRD+ advanced ovarian cancer?
Community PollStarted
What systemic therapy do you recommend for optimally debulked/low risk BRCA(-) HRD(+) ovarian cancer?
164 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Utah School of Medicine
Answered on · Updated on
We have a better understanding of ovarian cancer biology now, including the importance of germline and somatic BRCA mutations, as well as the role of homologous recombination deficiency (HRD) in tumors and the potential benefit of new therapies in the maintenance.
Considerations for maintenance thera...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Gynecologic Oncology · UCSD Moores Cancer Center
Answered on
Yes. In clinical practice, I discuss and recommend PARP inhibitor maintenance therapy for patients who are HRD+. This recommendation is informed by data from both PAOLA-1 as well as PRIMA clinical trials. In both of these studies, the magnitude of benefit with PARP inhibitor maintenance strategies w...
Join for free or sign in to see the full answer